Bioventix (BVXP) Stock Overview
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BVXP Community Fair Values
See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bioventix PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£21.50 |
| 52 Week High | UK£38.50 |
| 52 Week Low | UK£17.50 |
| Beta | 0.62 |
| 1 Month Change | -11.89% |
| 3 Month Change | -10.42% |
| 1 Year Change | -42.67% |
| 3 Year Change | -41.89% |
| 5 Year Change | -46.38% |
| Change since IPO | 1,002.56% |
Recent News & Updates
Bioventix (LON:BVXP) Will Pay A Dividend Of £0.80
Oct 30Lacklustre Performance Is Driving Bioventix PLC's (LON:BVXP) 26% Price Drop
Oct 29Recent updates
Shareholder Returns
| BVXP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | -1.1% |
| 1Y | -42.7% | 13.0% | 17.9% |
Return vs Industry: BVXP underperformed the UK Biotechs industry which returned 13.3% over the past year.
Return vs Market: BVXP underperformed the UK Market which returned 18.2% over the past year.
Price Volatility
| BVXP volatility | |
|---|---|
| BVXP Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BVXP has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: BVXP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 12 | Peter Harrison | www.bioventix.com |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results.
Bioventix PLC Fundamentals Summary
| BVXP fundamental statistics | |
|---|---|
| Market cap | UK£112.33m |
| Earnings (TTM) | UK£7.58m |
| Revenue (TTM) | UK£13.12m |
Is BVXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVXP income statement (TTM) | |
|---|---|
| Revenue | UK£13.12m |
| Cost of Revenue | UK£1.20m |
| Gross Profit | UK£11.92m |
| Other Expenses | UK£4.33m |
| Earnings | UK£7.58m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 90.86% |
| Net Profit Margin | 57.83% |
| Debt/Equity Ratio | 0% |
How did BVXP perform over the long term?
See historical performance and comparisonDividends
Does BVXP pay a reliable dividends?
See BVXP dividend history and benchmarks| Bioventix dividend dates | |
|---|---|
| Ex Dividend Date | Nov 06 2025 |
| Dividend Pay Date | Nov 21 2025 |
| Days until Ex dividend | 12 days |
| Days until Dividend pay date | 3 days |
Does BVXP pay a reliable dividends?
See BVXP dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 05:24 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioventix PLC is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
